$YTENQ
YIELD10 BIOSCIENCE, INC. Stock $ytenq

$ytenq Overview Financials Valuation SEC Filings Company Website

2016 Q1 Form 10-Q Financial Statement

#000112170216000061 Filed on May 16, 2016

Income Statement

Concept	2016 Q1	2015 Q1
Revenue	$157.0K	$645.0K
YoY Change	-75.66%	5.22%
Cost Of Revenue	$117.0K	$84.00K
YoY Change	39.29%	-49.4%
Gross Profit	$40.00K	$561.0K
YoY Change	-92.87%	25.5%
Gross Profit Margin	25.48%	86.98%
Selling, General & Admin	$2.272M	$2.466M
YoY Change	-7.87%	-21.26%
% of Gross Profit	5680.0%	439.57%
Research & Development	$1.430M	$3.930M
YoY Change	-63.61%	-18.3%
% of Gross Profit	3575.0%	700.53%
Depreciation & Amortization	$122.0K	$55.00K
YoY Change	121.82%	-71.2%
% of Gross Profit	305.0%	9.8%
Operating Expenses	$2.272M	$2.466M
YoY Change	-7.87%	-21.26%
Operating Profit	-$3.543M	-$5.830M
YoY Change	-39.23%	-22.17%
Interest Expense	$3.000K	$1.000K
YoY Change	200.0%	-80.0%
% of Operating Profit
Other Income/Expense, Net	$3.000K	-$13.00K
YoY Change	-123.08%	-316.67%
Pretax Income	-$3.540M	-$5.840M
YoY Change	-39.38%	-22.03%
Income Tax
% Of Pretax Income
Net Earnings	-$6.500M	-$5.843M
YoY Change	11.24%	-28.34%
Net Earnings / Revenue	-4140.13%	-905.89%
Basic Earnings Per Share
Diluted Earnings Per Share	-$92.86M	-$97.33M
COMMON SHARES
Basic Shares Outstanding	27.37M shares	135.4M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q1	2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.300M	$13.30M
YoY Change	-60.15%	27.88%
Cash & Equivalents	$5.271M	$13.26M
Short-Term Investments
Other Short-Term Assets	$1.900M	$800.0K
YoY Change	137.5%	-27.27%
Inventory	$420.0K	$555.0K
Prepaid Expenses
Receivables	$272.0K	$139.0K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$8.099M	$25.47M
YoY Change	-68.2%	59.04%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.352M	$743.0K
YoY Change	81.97%	62.94%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$717.0K	$95.00K
YoY Change	654.74%	0.0%
Total Long-Term Assets	$2.501M	$1.457M
YoY Change	71.65%	3.04%
TOTAL ASSETS
Total Short-Term Assets	$8.099M	$25.47M
Total Long-Term Assets	$2.501M	$1.457M
Total Assets	$10.60M	$26.93M
YoY Change	-60.63%	54.49%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$181.0K	$384.0K
YoY Change	-52.86%	-23.96%
Accrued Expenses	$2.654M	$3.184M
YoY Change	-16.65%	21.71%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.102M	$3.814M
YoY Change	-18.67%	-2.33%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$322.0K	$150.0K
YoY Change	114.67%	1.35%
Total Long-Term Liabilities	$322.0K	$150.0K
YoY Change	114.67%	1.35%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.102M	$3.814M
Total Long-Term Liabilities	$322.0K	$150.0K
Total Liabilities	$3.424M	$3.964M
YoY Change	-13.62%	-2.2%
SHAREHOLDERS EQUITY
Retained Earnings	-$332.3M	-$314.0M
YoY Change	5.82%	11.86%
Common Stock	$339.5M	$337.0M
YoY Change	0.74%	96467.05%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$7.176M	$22.96M
YoY Change
Total Liabilities & Shareholders Equity	$10.60M	$26.93M
YoY Change	-60.63%	54.49%

Cashflow Statement

Concept	2016 Q1	2015 Q1
OPERATING ACTIVITIES
Net Income	-$6.500M	-$5.843M
YoY Change	11.24%	-28.34%
Depreciation, Depletion And Amortization	$122.0K	$55.00K
YoY Change	121.82%	-71.2%
Cash From Operating Activities	-$6.526M	-$6.661M
YoY Change	-2.03%	-25.7%
INVESTING ACTIVITIES
Capital Expenditures	$161.0K	$127.0K
YoY Change	26.77%	27.0%
Acquisitions
YoY Change
Other Investing Activities	-$310.0K	$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$468.0K	-$130.0K
YoY Change	260.0%	-102.83%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		0.000
YoY Change		-100.0%
NET CHANGE
Cash From Operating Activities	-$6.526M	-$6.661M
Cash From Investing Activities	-$468.0K	-130.0K
Cash From Financing Activities		0.000
Net Change In Cash	-$6.994M	-$6.661M
YoY Change	5.0%	-25.7%
FREE CASH FLOW
Cash From Operating Activities	-$6.526M	-$6.661M
Capital Expenditures	$161.0K	$127.0K
Free Cash Flow	-$6.687M	-$6.788M
YoY Change	-1.49%	-25.12%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q1	dei	Amendment Flag AmendmentFlag	false
CY2016Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2016Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2016Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
CY2016Q1	dei	Document Period End Date DocumentPeriodEndDate	2016-03-31
CY2016Q1	dei	Document Type DocumentType	10-Q
CY2016Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001121702
CY2016Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	27369390	shares
CY2016Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2016Q1	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2016Q1	dei	Entity Registrant Name EntityRegistrantName	METABOLIX, INC.
CY2015Q4	mblx	Accrued Commercial Manufacturing Current AccruedCommercialManufacturingCurrent	465000	USD
CY2016Q1	mblx	Accrued Commercial Manufacturing Current AccruedCommercialManufacturingCurrent	257000	USD
CY2015Q1	mblx	Charge For Company Common Stock Match ChargeForCompanyCommonStockMatch	137000	USD
CY2016Q1	mblx	Charge For Company Common Stock Match ChargeForCompanyCommonStockMatch	155000	USD
CY2015Q2	mblx	Class Of Warrant Or Right Expiration Term ClassOfWarrantOrRightExpirationTerm	P4Y
CY2016Q1	mblx	Contractual Commitment Periodic Payment Obligation Service Fee ContractualCommitmentPeriodicPaymentObligationServiceFee	520	USD
CY2015Q1	mblx	Cost Of Revenue Research And Development Expenses CostOfRevenueResearchAndDevelopmentExpenses	3925000	USD
CY2016Q1	mblx	Cost Of Revenue Research And Development Expenses CostOfRevenueResearchAndDevelopmentExpenses	4332000	USD
CY2015Q1	mblx	Increase Decrease In Deferred Rent And Long Term Liabilities IncreaseDecreaseInDeferredRentAndLongTermLiabilities	0	USD
CY2016Q1	mblx	Increase Decrease In Deferred Rent And Long Term Liabilities IncreaseDecreaseInDeferredRentAndLongTermLiabilities	-150000	USD
CY2015Q1	mblx	License And Royalty Revenue LicenseAndRoyaltyRevenue	121000	USD
CY2016Q1	mblx	License And Royalty Revenue LicenseAndRoyaltyRevenue	197000	USD
CY2016Q1	mblx	Operatingleaseslandlordreimbforleaseimprovementsadditionalpayments Operatingleaseslandlordreimbforleaseimprovementsadditionalpayments	444	USD
CY2016Q1	mblx	Operatingleaseslandlordreimbursementforleaseimprovements Operatingleaseslandlordreimbursementforleaseimprovements	889	USD
CY2016Q1	mblx	Period Over Which Capital Resources Are Not Sufficient To Fund Planned Operations PeriodOverWhichCapitalResourcesAreNotSufficientToFundPlannedOperations	P12M
CY2015Q4	mblx	Stock Purchase Agreement Default Stock Price Trigger StockPurchaseAgreementDefaultStockPriceTrigger	0.50
CY2015Q2	mblx	Unit Price UnitPrice	0.125
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	120000	USD
CY2016Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	181000	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	238000	USD
CY2016Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	272000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3513000	USD
CY2016Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2654000	USD
CY2015Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	431000	USD
CY2016Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	866000	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-72000	USD
CY2016Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-76000	USD
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	338580000	USD
CY2016Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	339229000	USD
CY2015Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1102990	shares
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6034700	shares
CY2016Q1	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	30000	sqft
CY2015Q4	us-gaap	Assets Assets	17088000	USD
CY2016Q1	us-gaap	Assets Assets	10600000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	14850000	USD
CY2016Q1	us-gaap	Assets Current AssetsCurrent	8099000	USD
CY2015Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2016Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	476000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20046000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13257000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12269000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5271000	USD
CY2015Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	12269000	USD
CY2016Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	5271000	USD
CY2015Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.98
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2016Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22530322	shares
CY2016Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26981214	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22530322	shares
CY2016Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26981214	shares
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	136000000	shares
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23000000	shares
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	273000	USD
CY2016Q1	us-gaap	Common Stock Value CommonStockValue	274000	USD
CY2015Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5847000	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6502000	USD
CY2015Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	84000	USD
CY2016Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	117000	USD
CY2015Q1	us-gaap	Costs And Expenses CostsAndExpenses	6475000	USD
CY2016Q1	us-gaap	Costs And Expenses CostsAndExpenses	7176000	USD
CY2015Q4	us-gaap	Deferred Costs Current And Noncurrent DeferredCostsCurrentAndNoncurrent	51000	USD
CY2016Q1	us-gaap	Deferred Costs Current And Noncurrent DeferredCostsCurrentAndNoncurrent	45000	USD
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	277000	USD
CY2016Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	267000	USD
CY2015Q1	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	38885000	USD
CY2015Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	55000	USD
CY2016Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	122000	USD
CY2015Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	146000	USD
CY2016Q1	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	204000	USD
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.26
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.24
CY2015Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	-1000	USD
CY2016Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	-4000	USD
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2114000	USD
CY2016Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1104000	USD
CY2016Q1	us-gaap	Incentive To Lessee IncentiveToLessee	347	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-45000	USD
CY2016Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	84000	USD
CY2015Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	0	USD
CY2016Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	18000	USD
CY2016Q1	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
CY2016Q1	us-gaap	Investments And Cash InvestmentsAndCash	5271000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	71000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	129000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	34000	USD
CY2015Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1128000	USD
CY2016Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1051000	USD
CY2015Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	102000	USD
CY2016Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-10000	USD
CY2015Q1	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	-18000	USD
CY2016Q1	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	58000	USD
CY2015Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-15000	USD
CY2016Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	41000	USD
CY2015Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	18000	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-280000	USD
CY2015Q1	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
CY2016Q1	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	307000	USD
CY2015Q1	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	138000	USD
CY2016Q1	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	-97000	USD
CY2015Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1000	USD
CY2016Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	3000	USD
CY2015Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	328000	USD
CY2016Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	318000	USD
CY2015Q4	us-gaap	Inventory Net InventoryNet	379000	USD
CY2016Q1	us-gaap	Inventory Net InventoryNet	420000	USD
CY2015Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	51000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	4060000	USD
CY2016Q1	us-gaap	Liabilities Liabilities	3424000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17088000	USD
CY2016Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10600000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3910000	USD
CY2016Q1	us-gaap	Liabilities Current LiabilitiesCurrent	3102000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-6789000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-6998000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-127000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-468000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6661000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6526000	USD
CY2015Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5843000	USD
CY2016Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6498000	USD
CY2015Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-13000	USD
CY2016Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3000	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5830000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6501000	USD
CY2016Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	399	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	216	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	785	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	725	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	7346	USD
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	503000	USD
CY2016Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	427000	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	714000	USD
CY2016Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	717000	USD
CY2015Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-4000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-4000	USD
CY2015Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-4000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-4000	USD
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	150000	USD
CY2016Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	322000	USD
CY2015Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-14000	USD
CY2016Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2015Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	297000	USD
CY2015Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	127000	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	161000	USD
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2016Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	619000	USD
CY2015Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	22556383	shares
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27367305	shares
CY2016Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	494000	USD
CY2016Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2016Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1668000	USD
CY2016Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1385000	USD
CY2016Q1	us-gaap	Prepayment Fees On Advances Net PrepaymentFeesOnAdvancesNet	667	USD
CY2015Q2	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	14703000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	905000	USD
CY2016Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1352000	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	0	USD
CY2016Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	432000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-325753000	USD
CY2016Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-332251000	USD
CY2015Q1	us-gaap	Revenue From Grants RevenueFromGrants	452000	USD
CY2016Q1	us-gaap	Revenue From Grants RevenueFromGrants	157000	USD
CY2015Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	72000	USD
CY2016Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	321000	USD
CY2015Q1	us-gaap	Sales Revenue Net SalesRevenueNet	645000	USD
CY2016Q1	us-gaap	Sales Revenue Net SalesRevenueNet	675000	USD
CY2016Q1	us-gaap	Security Deposit SecurityDeposit	307	USD
CY2015Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2466000	USD
CY2016Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2727000	USD
CY2015Q1	us-gaap	Share Based Compensation ShareBasedCompensation	313000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	591000	USD
CY2015Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	300000	shares
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	13028000	USD
CY2016Q1	us-gaap	Stockholders Equity StockholdersEquity	7176000	USD
CY2015Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.1667
CY2015Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	150000	USD
CY2016Q1	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	53000	USD
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2016Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash and cash equivalents. The Company has historically invested its cash equivalents in highly rated money market funds, corporate debt, federal agency notes and U.S. treasury notes. Investments, when purchased, are acquired in accordance with the Company’s investment policy which establishes a concentration limit per issuer. At </font><font style="font-family:inherit;font-size:10pt;">March 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company’s cash equivalents are invested solely in money market funds.</font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company provides credit to customers in the normal course of business. The Company performs ongoing credit evaluations of its customers’ financial condition and limits the amount of credit extended when deemed necessary.</font></div></div>
CY2016Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America ("GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div>

Files In Submission

Name	View Source	Status
0001121702-16-000061-index-headers.html	Edgar Link	pending
0001121702-16-000061-index.html	Edgar Link	pending
0001121702-16-000061.txt	Edgar Link	pending
0001121702-16-000061-xbrl.zip	Edgar Link	pending
ex-311x20160331.htm	Edgar Link	pending
ex-312x20160331.htm	Edgar Link	pending
ex-321x20160331.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
mblx-20160331.xml	Edgar Link	completed
mblx-20160331.xsd	Edgar Link	pending
mblx-20160331x10q.htm	Edgar Link	pending
mblx-20160331_cal.xml	Edgar Link	unprocessable
mblx-20160331_def.xml	Edgar Link	unprocessable
mblx-20160331_lab.xml	Edgar Link	unprocessable
mblx-20160331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$YTENQ
YIELD10 BIOSCIENCE, INC. Stock $ytenq

2016 Q1 Form 10-Q Financial Statement

#000112170216000061 Filed on May 16, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$YTENQ YIELD10 BIOSCIENCE, INC. Stock $ytenq

2016 Q1 Form 10-Q Financial Statement

#000112170216000061 Filed on May 16, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$YTENQ
YIELD10 BIOSCIENCE, INC. Stock $ytenq